Logout Login Cart iconShop Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "【Order On Telegram: @Chem2Door】Buy Methylone (M1, MDMC) Online In San Francisco,.7007"

Looking for quality documents?
external link icon
Repligen Announces Proposed Public Offering of $100 Million of Convertible Senior Notes due 2021
WALTHAM, Mass., May 18, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) (the “Company”) has commenced an offering of $100 million aggregate principal amount of Convertible Senior Notes due 2021 (the “Notes”) in an underwritten offering which includes the grant to the underwriter of a 30-day option to purchase up to an additional $15 million aggregate principal amount of Notes.  Jefferies is the sole book-running manager for the offering. 
The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.  The Notes will be issued and sold pursuant to an automatically effective shelf registration statement (including a base prospectus) that was previously filed with the Securities and Exchange Commission (“SEC”). A preliminary prospectus supplement relating to this offering will be filed with the SEC. When available, copies of the
external link icon
Repligen Announces Private Convertible Transaction of $600 Million Principal Amount of 1.00% Convertible Senior Notes Due 2028 Through Exchange and New Subscription Agreements
WALTHAM, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ: RGEN) today announced that on December 6, 2023, it entered into privately negotiated exchange and/or subscription agreements with certain holders of its outstanding 0.375% Convertible Senior Notes due 2024 (the “2024 Notes”) and certain new investors, pursuant to which Repligen will issue $600 million aggregate principal amount of 1.00% Convertible Senior Notes due 2028 (the “New Notes”). Approximately $309.9 million principal amount of the New Notes will be issued in exchange for approximately $217.7 million principal amount of 2024 Notes (the “Exchange Transactions”) and approximately $290.1 million principal amount of the New Notes will be issued for cash (the “Subscription Transactions”, and together with the Exchange Transactions, the “Transactions”). The conversion price for the New Notes will initially be approximately $203.06 per share of Repligen’s common stock, which represents a conversion
external link icon
Repligen Corporation Announces Agreement to Acquire Bioprocess Systems Innovator ARTeSYN Biosolutions and Completes Acquisition of Non-Metallic Solutions
Proposed A RTeSYN a cquisition adds gold standard single - use downstream bioprocessing s ystems
Advances Repligen’s S ystems strategy in Filtration and Chromatography , c omplement ing TangenX ® F lat S heet cassettes and OPUS ® PP C Completes acquisition of Non-Metallic Solutions (NMS), complementing our recent acquisition of EMT and further strengthens our single-use flow paths, durable plastics and assembly portfolio
WALTHAM, Mass., Oct. 27, 2020 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-held ARTeSYN Biosolutions (“ARTeSYN”) for approximately $200 million, comprised of approximately $130 million in cash and approximately $70 million in Repligen common stock. ARTeSYN Biosolutions is projected to generate approximately $30 million in revenue (pro forma) in 2020, led by the success of its
video icon
Resuspension
The off bottom lift promotes a quick and efficient resuspension of settled solids. 
news icon
Repligen Appoints Martin D. Madaus to Board of Directors
news icon
Announcing the 2014 North America Technology Fast 500™ Rankings: Annual ranking of fastest growing North America companies
video icon
Running a Recipe
Running a fully automated cGMP process has never been easier. From recipe upload to completion, the software is here to make sure you stay on track.​
corporate icon
Perfusion Cell Culture
Perfusion, a cornerstone of upstream continuous bioprocessing, has been practiced since the 1980s to maximize facility utilization, expand process flexibility and minimize costs. Today, novel cell retention devices and single-use technologies, with sophisticated control logic, simplify implementation.
external link icon
Repligen to Present at BIO CEO & Investor Conference
external link icon
Repligen to Present at the BIO CEO & Investor Conference